1. Home
  2. ITRM vs NEPH Comparison

ITRM vs NEPH Comparison

Compare ITRM & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITRM
  • NEPH
  • Stock Information
  • Founded
  • ITRM 2015
  • NEPH 1997
  • Country
  • ITRM Ireland
  • NEPH United States
  • Employees
  • ITRM N/A
  • NEPH N/A
  • Industry
  • ITRM Biotechnology: Pharmaceutical Preparations
  • NEPH Medical/Dental Instruments
  • Sector
  • ITRM Health Care
  • NEPH Health Care
  • Exchange
  • ITRM Nasdaq
  • NEPH Nasdaq
  • Market Cap
  • ITRM 40.0M
  • NEPH 36.1M
  • IPO Year
  • ITRM 2018
  • NEPH 2004
  • Fundamental
  • Price
  • ITRM $0.97
  • NEPH $3.98
  • Analyst Decision
  • ITRM Strong Buy
  • NEPH Buy
  • Analyst Count
  • ITRM 2
  • NEPH 1
  • Target Price
  • ITRM $7.00
  • NEPH $5.00
  • AVG Volume (30 Days)
  • ITRM 501.9K
  • NEPH 66.9K
  • Earning Date
  • ITRM 08-13-2025
  • NEPH 08-07-2025
  • Dividend Yield
  • ITRM N/A
  • NEPH N/A
  • EPS Growth
  • ITRM N/A
  • NEPH N/A
  • EPS
  • ITRM N/A
  • NEPH 0.08
  • Revenue
  • ITRM N/A
  • NEPH $15,517,000.00
  • Revenue This Year
  • ITRM N/A
  • NEPH $17.06
  • Revenue Next Year
  • ITRM $270.19
  • NEPH $12.20
  • P/E Ratio
  • ITRM N/A
  • NEPH $53.08
  • Revenue Growth
  • ITRM N/A
  • NEPH 10.34
  • 52 Week Low
  • ITRM $0.81
  • NEPH $1.36
  • 52 Week High
  • ITRM $3.02
  • NEPH $5.00
  • Technical
  • Relative Strength Index (RSI)
  • ITRM 45.02
  • NEPH 55.90
  • Support Level
  • ITRM $0.93
  • NEPH $3.83
  • Resistance Level
  • ITRM $1.03
  • NEPH $4.39
  • Average True Range (ATR)
  • ITRM 0.04
  • NEPH 0.48
  • MACD
  • ITRM 0.00
  • NEPH -0.06
  • Stochastic Oscillator
  • ITRM 29.23
  • NEPH 40.35

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: